Literature DB >> 1888198

High molecular weight glycosaminoglycans in AA type amyloid fibril extracts from human liver.

J H Magnus1, S O Kolset, G Husby.   

Abstract

Glycosaminoglycans have previously been identified in extracts of AA type hepatic amyloid fibril from a patient with amyloidosis associated with juvenile rheumatoid arthritis. The macromolecular properties of these polysaccharides are described here in more detail. By gel filtration and ion exchange chromatography glycosaminoglycans in the form of high molecular weight free chains were shown to coisolate with water extracted amyloid fibrils. About 60% of these were characterised as galactosamines (chondroitin sulphate/dermatan sulphate), whereas the remaining 40% consisted of N-sulphated glucosamines (heparin/heparan sulphate). The amyloid associated glycosaminoglycans were not part of intact proteoglycans in the fibril extracts.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1888198      PMCID: PMC1004488          DOI: 10.1136/ard.50.8.562

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  27 in total

1.  The potential significance of sulphated glycosaminoglycans as a common constituent of all amyloids: or, perhaps amyloid is not a misnomer.

Authors:  R Kisilevsky; A Snow
Journal:  Med Hypotheses       Date:  1988-08       Impact factor: 1.538

2.  Isolation and characterization of proteoglycans.

Authors:  D Heinegård; Y Sommarin
Journal:  Methods Enzymol       Date:  1987       Impact factor: 1.600

3.  Mucopolysaccharides of whole human spleens in generalized amyloidosis.

Authors:  T Bitter; H Muir
Journal:  J Clin Invest       Date:  1966-06       Impact factor: 14.808

4.  A method for the determination of the molecular weight and molecular-weight distribution of chondroitin sulphate.

Authors:  A Wasteson
Journal:  J Chromatogr       Date:  1971-07-08

5.  Comparative studies of the high molecular weight amyloid fibril proteins and similar components from normal tissues.

Authors:  D L Scott; G Marhaug; G Husby
Journal:  Clin Exp Immunol       Date:  1983-06       Impact factor: 4.330

6.  Amyloid fibril protein subunit, "protein AS": distribution in tissue and serum in different clinical types of amyloidosis including that associated with myelomatosis and Waldenström's macroglobulinamia.

Authors:  G Husby; K Sletten; T E Michaelsen; J B Natvig
Journal:  Scand J Immunol       Date:  1973       Impact factor: 3.487

7.  Immunohistochemical identification of heparan sulphate proteoglycan in secondary systemic amyloidosis.

Authors:  B Norling; G T Westermark; P Westermark
Journal:  Clin Exp Immunol       Date:  1988-08       Impact factor: 4.330

8.  Characterization of tissue and plasma glycosaminoglycans during experimental AA amyloidosis and acute inflammation. Qualitative and quantitative analysis.

Authors:  A D Snow; R Kisilevsky; C Stephens; T Anastassiades
Journal:  Lab Invest       Date:  1987-06       Impact factor: 5.662

9.  The role of fibronectin in the development of experimental amyloidosis. Evidence of immunohistochemical codistribution and binding property with serum amyloid protein A.

Authors:  E Kawahara; M Shiroo; I Nakanishi; S Migita
Journal:  Am J Pathol       Date:  1989-06       Impact factor: 4.307

10.  The amyloid P-component (protein AP): an integral part of the amyloid substance?

Authors:  M Holck; G Husby; K Sletten; J B Natvig
Journal:  Scand J Immunol       Date:  1979       Impact factor: 3.487

View more
  2 in total

1.  On the association between amyloid fibrils and glycosaminoglycans; possible interactive role of Ca2+ and amyloid P-component.

Authors:  T Stenstad; J H Magnus; K Syse; G Husby
Journal:  Clin Exp Immunol       Date:  1993-10       Impact factor: 4.330

2.  Isolation and partial characterization of heparan sulphate proteoglycans from human hepatic amyloid.

Authors:  J H Magnus; T Stenstad; G Husby; S O Kolset
Journal:  Biochem J       Date:  1992-11-15       Impact factor: 3.857

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.